The lung cancer program of Alliance Against Cancer. Ruggero De Maria, President
|
|
- Julie Thomas
- 5 years ago
- Views:
Transcription
1 The lung cancer program of Alliance Against Cancer Ruggero De Maria, President
2 Alliance Against Cancer (ACC) was established in 2002 by the Italian Ministry of Health with the task of promoting an active collaboration among Italian cancer institutes/associations through the exchange of information, knowledge, data, scientific results and human resources, and to respond in an appropriate and harmonised way to the building of the Italian and European strategy in oncology, at the level of both patient treatment and research. With more than 3,000 beds, about 250,000 patients treated annually, and more than 5,000 scientists and clinicians working on different aspects of oncology, ACC develops new approaches in prevention, early diagnosis, treatment and rehabilitation, while promoting the diffusion of state of the art cancer care in Italy.
3
4 NUMBERS Research performance of ACC Institutes Number of publications: > 5,000 / year Impact Factor: > 20,000 / year Research Grants: ~215,000,000 Euros (2014) New cancer patients every year: ~ 90,000 Active Clinical Trials: >1,000 (2014)
5 MAJOR PUBBLICATIONS (2016)
6 Information is the first therapy for cancer patients 39 information points in the major cancer centers Help line Mon-Fri from 9 a.m. to 7 p.m. AIMaC Information therapy forumtumore.aimac.it 34 booklet
7 28 Partners 19 Countries 15 Member states 3 Associated countries 1 Third country
8 May 2, 2016
9 MD Anderson Global MDACC Sister Institutions Co-Branded Institutions
10 IST IEO INT ISS IDI Humanitas Pascale HSR Besta Maugeri CRO IOV IOR IRE CROB Bari OPBG Meldola Reggio Emilia Gaslini IRCC Candiolo Lung Breast Colon ACC Working Groups Brain Melanoma Sarcoma
11 ACC Program for Precision Medicine Preclinical To develop a preclinical platform for in vitro screening of cancer drugs followed by simulation of clinical trials in avatar models to provide solid bases for effective clinical trials Clinical Phase I To validate among ACC Institutes proprietary NGS panels able to detect all actionable and major driver alterations, with the aim of obtaining a low-cost full characterization of all the tumors requiring molecular diagnostics while fostering innovative clinical trials Clinical Phase II To transfer the last innovations on liquid biopsy and transcriptome analysis to the routine diagnostics, while analyzing innovative biomarkers for immunotherapy
12 MRI Diagnosis and tissue banking H&E NGS Tumor dissociation and culture DNA RNA Biomarker-driven preclinical trials Tumorsphere expansion Banking GBM, Sarcoma, Melanoma, Colorectal, Lung, Breast and Renal carcinomas
13 Precision Medicine challenging and opportunities About 5% of Cancer Patients can be treated with the available FDA approved drugs, based on analyses of driver mutations However 40.2% of Patients can be treated with FDA approved drugs after repurposing 73.3% Patients (33.1% Further Patients) can be treated with drugs in Clinical Trials 39% of Patients can Receive Combination Therapies using FDAapproved Drugs + Drugs in Clinical Trials
14 : 315 genes, 28 gene fusions
15 Oncomine is an available Low-Cost Lung Cancer Panel Ion AmpliSeq Colon and Lung Cancer Panel Covers known (> 500) and novel mutations in 91 hotspot regions in 22 genes relevant to colon and lung tumorigenesis: KRAS, EGFR, BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MEK1, ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBXW7, FGFR3, NOTCH1, ERBB4, FGFR1, FGFR2 Ion AmpliSeq RNA Fusion Lung Cancer Research Panel ALK ROS1 RET NTRK1 EML4, HIP1, KIF5B, KLC1, TPR CD74, EXR, GOPC, LRIG3, SDC4, SLC34A2, TPM3 CCDC6, CUX1, KIF5B CEL, NFASC, IRF2BP2, TFG, QSTM1, SSBP2, DYNC2H1, CD74, MPRIP
16 How to approach the Precision Medicine issue in oncology?
17 ACC Genomics The Lung-Oncochip 1. Genes (all coding sequences, amplifications, deletions ) Total: 182 Actionables: 164 Drivers: Translocations/Rearrangements (RNA) - 93 Total fusion targets - 52 Actionable partner pairs (including ALK, RET, ROS1) 3. Germline Variants - Identified in the pharmgkb database - 87 genes; (141 variants)
18 A. Actionable Genes: ACC-Lung Panel: 182 full Genes ABL1 BRCA2 DNMT3A FGFR4 JAK2 MMP2 PDGFRA RARA TYK2 ABL2 BTK DOT1L FH JAK3 MPL PDGFRB RET VEGFA AKR1B1 CBFB EGFR FKBP5 KDR MST1R PGF RICTOR VEGFB AKT1 CCND1 EPHA1 FLCN KIT MTOR PGR ROS1 YES1 AKT2 CCND2 EPHA2 FLT1 KMT2A MYCN PIK3C2B RUNX1 AKT3 CCND3 EPHA3 FLT3 LCK MYD88 PIK3CA SLTM ALK CCNE1 EPHA4 FLT4 LYN NCOR2 PIK3CB SMARCB1 APC CDK4 EPHB2 FUS MAP2K1 NF1 PIK3CD SMO AR CDK6 ERBB2 FYN MAP2K2 NF2 PIK3R1 SMOX ARAF CDKN1B ERBB3 GNA11 MAP2K4 NOTCH1 PIK3R2 SRC ATM CDKN2A ERBB4 GNAQ MAP3K1 NOTCH2 PIP5K1A STK11 ATR CDKN2B ERCC2 HDAC9 MAP3K11 NOTCH3 PLCG2 STK4 AURKA CDKN2C ESR1 HGF MAP3K4 NOTCH4 PML SYK AURKB CHEK2 EZH2 HRAS MAP4K1 NPM1 PRKCZ TAOK1 AURKC CSF1R FBXW7 HSP90AA1 MAPK1 NRAS PTCH1 TAOK2 BAP1 CSF3R FGF3 IDH1 MAPK8 NTRK1 PTEN TEK BCL2 CTNNB1 FGF4 IDH2 MDM2 NTRK2 PTPN11 TET2 BCR DDR1 FGFR1 IGF1R MET NTRK3 RAC1 TOP2A BRAF DDR2 FGFR2 IGF2 MGMT PALB2 RAD50 TSC1 BRCA1 DNMT1 FGFR3 JAK1 MITF PDGFB RAF1 TSC2 B. Driver Genes: 164 genes with the following characteristics: FDA approved drug targets Clinical Trial drug targets In any cancer ACVR1B EPB41L3 KRAS PIK3CA SLTM ARID1A ERBB2 LRP1B POTEF SMARCA4 ATM FBXW7 MAP2K1 PTEN STK11 BRAF FGFR2 NAV3 RB1 TP53 CDKN2A HRAS NF1 RBM10 U2AF1 CRIPAK KEAP1 NFE2L2 SETBP1 EGFR KMT2D NOTCH1 SETD2 33 genes identified as driver by at least 2 out of 6 bioinformatics pipeline on LUSC, LUAD and NSCLC cancer types: DOTS-Finder, MuSiC, MutSig, OncodriveCLUST/FM, TUSONexplorer, Vogelstein approach (used as confirmation) In bold, genes that are both driver and actionable
19 ACC-Lung Panel: 93 fusion genes Actionable Translocations and Rearrangements EML4-ALK CTNNA3-IGF2 NF1-PSDM11 CLTC-ROS1 HIP1-ALK EML4-ALK ECHDC1-FYN CTNNA3-IGF2 CD74-NTRK1 NF1-PSDM11 GOPC-ROS1 CLTC-ROS1 KIF5B-ALK HIP1-ALK RBM14-FGF3 ECHDC1-FYN MPRIP-NTRK1 CD74-NTRK1 LRIG3-ROS1 GOPC-ROS1 KLC1-ALK KIF5B-ALK FGFR2-KIAA1967 RBM14-FGF3 BFSP2-PIK3CB MPRIP-NTRK1 SDC4-ROS1 LRIG3-ROS1 PTPN3-ALK KLC1-ALK FGFR3-TACC3 FGFR2-KIAA1967 PIP5K1A-C1orf56 BFSP2-PIK3CB SLC34A2-ROS1 SDC4-ROS1 STRN-ALK PTPN3-ALK IKZF3-NF1 FGFR3-TACC3 SKI-PRKCZ PIP5K1A-C1orf56 KIF5B-RET SLC34A2-ROS1 TFG-ALK STRN-ALK JARID2-ATM IKZF3-NF1 CCDC6-RET SKI-PRKCZ TPM3-ROS1 KIF5B-RET TPR-ALK TFG-ALK KDM2A-DDR2 JARID2-ATM CUX1-RET CCDC6-RET SCAF11-PDGFRA TPM3-ROS1 TPR-ALK KDM2A-DDR2 CUX1-RET SCAF11-PDGFRA BRAF-SLC6A4 KIAA0182-NOTCH3 NCO4-RET SPINT2-MAP4K1 CAPZA2-MET KIF5B-MET TRIM33-RET STK11-HMHA1 KRAS-CDH13 LRP1B-HECW2 CCDC6-ROS TAOK1-ZNF385C CDKN2A-FOCAD MDM2-NUP107 CD74-ROS1 TRIM24-NTRK2 FGFR2-CIT MST1R-FNDC3B EZR-ROS1 USP32-EPHA1 52 actionable partner pairs (at least one of the genes is actionable) derived from lung cancer data: Atlas of Genetics and Cytogenetics in Oncology and Haematology Vogelstein, Science 2013 COSMIC To be performed on cdna
20 ACC-Lung Panel: 87 pharmacogenomic variants ABCB1 CYP19A1 EPHX1 HSPA5 RRM2 TMEM43,XPC ABCB1 CYP19A1 EPHX1 HSPA5 RRM2 TMEM43,XPC ABCC1 CYP1A1 ERBB2 HTR2A RRM2B TP53 ABCC2 CYP1B1 ERCC1 KLC1,XRCC3 SHMT1 TPMT ABCC3 CYP2B6 ERCC2 LRP2 SLC10A2 TYMS ABCC4 CYP2C19 ERCC2,KLC3 MTHFR SLC19A1 UGT1A1 ABCG2 CYP2C8 ESR1 NAT2 SLC22A12 UGT1A4 AKT1 CYP2D6 FCGR3A NOS3 SLC22A16 UGT1A8 BAIAP3 CYP2E1 FDPS NQO1 SLC22A2 UGT1A9 C8orf34 CYP3A4 FMO3 NQO2 SLC28A3 UMPS CASP7 CYP3A5 GALNT14 NRP2 SLC31A1 XRCC1 CBR1 DCBLD1 GRIN2B PARD3B SLC6A4 XRCC4 CBR3 DPYD GSTP1 PIK3CA SLCO1B1 ZNF423 CCND1 DSCAM HLA-DQB1 PRDX4 SLCO1B3 CDA EGF HMGCR RHBDF2 SOD2 COMT EGFR HNMT RRM1 SULT2B1 Clinical variants extracted from pharmacogenomics database (PharmGKB) Only point variant included in assay Sometimes overlapping with full genes (and included in full-gene design)
21 PERCENTAGE OF COVERED Pts. AVERAGE NR OF ACTIONABLE MUTATIONS PER Pt. The ACC Lung-Cancer Chip ACC Genomics 164 Actionable Genes 52 Actionable Fusions 96 Actionable SNPs 18 Driver Genes 5 Driver Fusions Cost: <300 per patient 99% Patients with 1 actionable mutation Actionable mutations per patient ACC: ~4.5 80% ACC: 97% 60% Foundation One: 93% Foundation One: ~3.5 40% 20% Oncomine: 25% Oncomine: 0.25 GENOMIC SPACE GENOMIC SPACE Kb: Kb: In silico screening of ~500 lung-cancer patients
22 Gene Mutated tumors ACC Genomics Most frequently mutated ACTIONABLE genes in lung ADC ACC Foundation One Oncomine STK11 80 yes yes yes EGFR 73 yes yes yes NF1 64 yes yes KDR 50 yes yes NOTCH4 49 yes ERBB4 47 yes yes yes ATM 46 yes yes HDAC9 46 yes HGF 46 yes yes EPHA3 45 yes yes NTRK3 42 yes yes BRAF 41 yes yes yes CHEK2 39 yes yes PDGFRA 38 yes yes ALK 33 yes yes yes NOTCH2 32 yes yes
23 ACC Genomics Most frequently mutated DRIVER genes in lung ADC Gene Mutated tumors ACC Foundation One Oncomine TP yes yes yes LRP1B 192 yes yes KRAS 164 yes yes yes NAV3 118 yes KEAP1 96 yes yes SETBP1 59 yes KMT2D 51 yes yes ARID1A 44 yes yes SMARCA4 43 yes yes RBM10 36 yes yes SETD2 33 yes yes RB1 31 yes yes EPB41L3 30 yes
24 Validation of the Alliance Against Cancer lung panel in 1,000 patients with Non Small Cell Lung Cancer
25 Secondary Objectives 1. To determine the percentage of enrolled NSCLC patients with an adequate amount of tissue to perform molecular analyses with standard methods. 2. To investigate the percentage of cases evaluated by NGS > (at least 90%). 3. To evaluate the frequency of the oncogenic alterations identified by NGS in comparison with the data from literature. 4. To evaluate the frequency of the oncogenic alterations (presence of KRAS mutations, ROS-1 fusions, MET exon 14 skipping mutations and BRAF mutations), identified by NGS, in comparison with standard methods.
26 Secondary Objectives 5. To evaluate the proportion of patients carrying mutations, for which an approved targeted therapy is available, according to National and International Guidelines, that have received the recommend therapy > (at least 90%). 6. To evaluate the performance of each center in terms of sensitivity, specificity and percentage of successful molecular characterization by NGS of EGFR activating mutations and EML4-ALK rearrangements. 7. To measure the time interval to obtain the molecular results (within 4 weeks from the first patient s visit to biopsy and within 10 working days from the biopsy to the final written report of molecular analyses performed). 8. To measure OS and PFS
27 Clinical Value of the Germline Actionable-Genome
28 The ACC-GerSom Gene-Panel: the phylosophy 1. Genomic profile of every patient (tumor+germline) Identification of actionable somatic mutations Identification of germline pharmacogenomic variants Identification of drivergene mutations Treatmentstratification Drug-toxicity New stratification markers Identification of Germline cancer-risk variants 2. Mapping of each risk-variant In family members Cancerprevention plans Registry of Somatic cancer-mutations Registry of Germline cancer-risk variants
29 Second Gene-Panel Strategy (Onco-Chip) The Actionable Genome (same for all tumor types) Somatic Actionability (164 genes) Germline Actionability (126 genes) Drug- Toxicity Actionability (87 genes) The Tumor-Driver Genome (tumor-type specific) Drivers identified with public and proprietary bioinformatic pipelines (385 genes) bp 9 Cancer-types: Breast, Ovary cancer Lung Cancer Colo-rectal Cancer Prostate cancer Melanomas Renal Cancer Glioblastomas Neuroendocrine tumors
30 GERMSOM Panel 1 ABL2 DOT1L JAK3 PDGFRB VEGFA NCOR1 MED12 FAM175A XPC AKR1B1 EGFR KDR PGF VEGFB RBMX U2AF1 GEN1 FANCE AKT1 EPHA1 KIT PGR YES1 SF3B2 BCOR HOXB13 WRN AKT2 EPHA2 KMT2A PIK3C2B ELANE SPEN WT1 MRE11A NBN AKT3 EPHA3 LCK PIK3CA SMARCE1 TBL1XR1 CEBPA PALLD EXT1 ALK EPHA4 LYN PIK3CB TP53 TBX3 DDX3X RAD51 RECQL4 APC EPHB2 MAP2K1 PIK3CD ARID1A ZFP36L1 WAS XRCC2 FANCG AR ERBB2 MAP2K2 PIK3R1 KMT2D CDH1 SMARCA4 XRCC3 FANCC ARAF ERBB3 MAP2K4 PIK3R2 NFE2L2 MSH3 HLA-A COL7A1 XPA ATM ERBB4 MAP3K1 PIP5K1A RB1 POLD1 MYC DOCK8 BMPR1A ATR ERCC2 MAP3K11 PLCG2 SETD2 RMRP TERT HFE CDKN1C AURKA ESR1 MAP3K4 PML KDM6A ACVR1B KMT2C POLH FANCF AURKB EZH2 MAP4K1 PRKCZ STAG2 RBM10 SMAD4 SDHA EXT2 AURKC FBXW7 MAPK1 PTCH1 ELF3 AMER1 RNF43 SLC25A13 DDB2 BAP1 FGF3 MAPK8 PTEN ARHGAP35 AXIN2 LRP1B SRY CEP57 BCL2 FGF4 MDM2 PTPN11 EP300 B2M CBL TGFBR1 ERCC5 BCR FGFR1 MET RAC1 FAT1 PCBP1 ITK SDHB FANCM BRAF FGFR2 MGMT RAD50 FRG1B SMAD2 CRIPAK MUTYH BUB1B BRCA1 FGFR3 MITF RAF1 IL32 SOX9 KEAP1 SDHC FANCI BRCA2 FGFR4 MMP2 RARA MGAM TCF7L2 NAV3 EPCAM BLM BTK FH MPL RET GBA CDC27 POTEF MSH2 SLX4 CBFB FKBP5 MST1R RICTOR RPSAP58 ACVR2A SETBP1 TMEM127 ERCC4 CCND1 FLCN MTOR ROS1 FAH HMBS DIS3L2 PMS1 FANCA CCND2 FLT1 MYCN RUNX1 SLC9A9 UROD EPB41L3 MLH1 PRKAR1A CCND3 FLT3 MYD88 SLTM GJB2 AJUBA ARID1B GATA2 FANCB CCNE1 FLT4 NCOR2 SMARCB1 MTAP CYLD PPP6C PHOX2B GPC3 CDK4 FUS NF1 SMO TRIM37 HLA-B STK19 PMS2 MSH6 CDK6 FYN NF2 SMOX KRAS NSD1 CDK12 SBDS AIP CDKN1B GNA11 NOTCH1 SRC AOAH RASA1 PRSS1 SUFU CDKN2A GNAQ NOTCH2 STK11 ARID2 RHOA DKC1 SDHAF2 CDKN2B HDAC9 NOTCH3 STK4 ATN1 TGFBR2 MEN1 SDHD CDKN2C HGF NOTCH4 SYK CASP8 ZNF750 OR2T35 RAD51D CHEK2 HRAS NPM1 TAOK1 CTCF GUSB SPOP RAD51C CSF1R HSP90AA1 NRAS TAOK2 FOXA1 KDM5C PGM5 BRIP1 CSF3R IDH1 NTRK1 TEK FZR1 PBRM1 DICER1 RHBDF2 CTNNB1 IDH2 NTRK2 TET2 GATA3 VHL PPM1D PRF1 DDR1 IGF1R NTRK3 TOP2A HIST1H3B FAS MAX CDC73 DDR2 IGF2 PALB2 TSC1 HNF1A SERPINA1 POLE FANCL DNMT1 JAK1 PDGFB TSC2 MED23 SH2D1A SOS1 ERCC3 DNMT3A JAK2 PDGFRA TYK2 MYB STAT3 BARD1 FANCD2 ACTIONABLE ALL BLADDER BRAIN BREAST COLON HEAD AND NECK KIDNEY LEUKEMIA LIMPH NODES LIVER MELANOMA OVARY PANCREAS PROSTATE STOMACH THYROID UTERUS RISK
31 The ACC Prescription Database: Goals Genomic database Create large-scale data resources of genomic information: Mutational Database Actionability infos Link the genomic database to: to EMRs and Health-System databases to research pipelines Interface with Doctors Create widely accepted and controlled vocabularies (ontologies) for clinical phenotypes Generate standards and pipelines for data interpretation and clinical decision support (automated decision support tools for clinicians) Interface with patients Train patients in using genomic information Give patients access to the latest experimental protocols and drugs
32 THE ACC PRESCRIPTION DATABASE Id: entry id Type: type of mutation (SNV, CAN, germline, translocation or other) Disease: the disease for which that relationship is observed Drug name: merges drug category/drug name Exact alteration: site of mutation if SNV, amp o del se CAN, translocation partner se translocation Act status: the contest in which the relationship is observed Act type: predicts sensitivity or resistance, prognostic (nothing else) Source: one of the four original databases (Cancer Discovery, Mills, Target (Broad), Intogen) or ACC References: Pubmed ID of the supporting paper Clinical trials: clinical trials.gov ID of available trials (in development)
33 Cancer stem cells Shared Database and Biobank WG GLIOMA Enrollment Avatar Omics analysis Preclinical validation Genomics-driven clinical trial
34
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationJennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA
Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology
More informationJocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic
Jocelyn Chapman, MD Division of Gynecologic Oncology Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Genetics underlies all cancers Somatic or tumor genetics Germline or inherited genetics
More informationPrecision Oncology: Experience at UW
Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,
More informationIllumina s Cancer Research Portfolio and Dedicated Workflows
Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,
More informationClinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD
Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial
More informationDNA Genetic Cancer Risk Test. Test Report
Test Report CONTENTS SECTION 1 1-1. Customer Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Cancers / Tumors Tested SECTION 2 2-1. About the Test 2-2. References 1 CL0040-1_B
More informationChanging the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle
Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationAssessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center
Assessing the Economics of Genomic Medicine Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center DISCLOSURES No conflicts Patents unenforced Consultancies unpaid
More information# 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide
# 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide PositiveSelect is India s widely used Cancer Genomics test with every 8 out of 10 patients opting
More informationProvide your cancer patients personalized treatment options with ClariFind
ONCOLOGY ClariFind employs next-generation sequencing (NGS) for comprehensive genomic profiling of a patient s tumor sample to identify potential clinically actionable targets and associated therapies.
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationpatient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationExons from 137 genes were targeted for hybrid selection and massively parallel sequencing.
SUPPLEMENTARY TABLES Supplementary Table 1. Targeted Genes ABL1 ABL2 AKT1 AKT2 AKT3 ALK APC ATM AURKA BCL2 BRAF BRCA1 BRCA2 CCND1 CCNE1 CDC73 CDH1 CDK4 CDK6 CDK8 CDKN1A CDKN2A CEBPA CHEK1 CHEK2 CREBBP
More informationWhat is the status of the technologies of "precision medicine?
Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Frampton et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Supplementary Figure 1A Base substitution detection
More informationSample Metrics. Allele Frequency (%) Read Depth Ploidy. Gene CDS Effect Protein Effect. LN Metastasis Tumor Purity Computational Pathology 80% 60%
Supplemental Table 1: Estimated tumor purity, allele frequency, and independent read depth for all gene mutations classified as either potentially pathogenic or VUS in the metatastic and primary tumor
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:1.138/nature12912 Figure S1. Distribution of mutation rates and spectra across 4,742 tumor-normal (TN) pairs from 21 tumor types, as in Figure 1 from Lawrence et al. Nature
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 8 1.5. Primary Tumour Description... 10 1.6.
More informationTable S1. Demographics of patients and tumor characteristics.
Supplemental Tables for: A Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers Kim Hirshfield et al. Table S1. Demographics of patients and tumor characteristics.
More informationGenomics in the Clinical Practice - Today and Tomorrow
Genomics in the Clinical Practice - Today and Tomorrow Pier Giuseppe Pelicci, MD-PhD Director of Research, IEO, Milan Professor of Pathology, University of Milan Workshop on Processing of Genomic Information:
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationA CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST. Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol
A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol Topics to be covered How pathology contributes to genetic diagnosis
More informationHematology Fusion/Expression Profile
Hematology Fusion/Expression Profile Patient Name: Ordered By Date of Birth: Ordering Physician: Gender (M/F): Physician ID: Client: Accession #: Case #: Specimen Type: Body Site: Specimen ID: Ethnicity:
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationI have no conflicts of interest
Deploying lung cancer molecular pathology guidelines in real life Neal Lindeman, MD Director, Molecular Pathology Brigham & Women s Hospital USCAP Annual Meeting AMP Companion Meeting San Antonio, T Sunday,
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationDiagnostica Molecolare!
Diagnostica Molecolare! Aldo Scarpa Unità Diagnostica Molecolare Azienda Ospedaliera Universitaria Integrata di Verona e ARC-NET Centro di Ricerca Applicata sul Cancro PDTA CARCINOMA POLMONARE - IL PAZIENTE
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More informationIMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY
Madrid, Spain IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Dr. JL Rodríguez Peralto NGS Ion Torrent Oncomine Focus Assay - Implementation experience for EGFR mutation detection
More informationOncology Update: The 10 Most Talked About Breast Cancer Topics of The Top 10 10/24/2013. The Awareness Debate
Oncology Update: The 10 Most Talked About Breast Cancer Topics of 2013 Michaela Tsai, MD Martha Bacon Stimpson Chair of Breast Oncology Virginia Piper Cancer Institute Minnesota Oncology The Top 10 1.
More informationDiagnostic and Treatment of Patients with Primary and Metastatic Breast Cancer
Diagnostic and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Versions 2003 2017: Schmutzler / Albert / Blohmer / Fasching
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationClick to edit Master /tle style
Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics
More informationWhy Pathway/Network Analysis?
6/8/16 More Depth on Pathway and Network Analysis Lincoln Stein Why Pathway/Network Analysis? Drama@c data size reduc@on: 1000 s of genes => dozens of pathways. Increase sta@s@cal power by reducing mul@ple
More informationMOLECULAR SERVICES. mlabs.umich.edu
MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service
More informationPRESENTAZIONE DI RUGGERO DE MARIA
Iniziativa realizzata con il contributo di Pfizer Roma, 17 ottobre 2018 Sala Zuccari, Palazzo Giustiniani PRESENTAZIONE DI RUGGERO DE MARIA La ricerca oncologica e le prospettive per il sistema Prof. Ruggero
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationParadigm Cancer Diagnostic (PCDx)
Paradigm Cancer Diagnostic (PCDx) Date of Birth: PCDx Case#: Physician: Facility: PCDx-18-0XXXX Case/Specimen ID: Collection Site: Collection Date: Received for testing: Turnaround: 4 business days Tumor
More informationClinical implication of MEN1 mutation in surgically resected thymic carcinoid patients
Case Report Clinical implication of MEN1 in surgically resected thymic carcinoid patients Xiongfei Li 1 *, Mingbiao Li 1 *, Tao Shi 2 *, Renwang Liu 1, Dian Ren 1, Fan Yang 1, Sen Wei 1, Gang Chen 1, Jun
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More informationSecuenciación masiva: papel en la toma de decisiones
Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationIdentification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins
Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins February 3-5, 2016 Lansdowne Resort, Leesburg, VA Molecular
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Page 1 of 35 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Cancer Susceptibility
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2018 Origination: 7/2013 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationSupplemental Information. Whole-Genome Sequencing. of a Healthy Aging Cohort
Cell, Volume 165 Supplemental Information Whole-Genome Sequencing of a Healthy Aging Cohort Galina A. Erikson, Dale L. Bodian, Manuel Rueda, Bhuvan Molparia, Erick R. Scott, Ashley A. Scott-Van Zeeland,
More informationList of diseases covered by Cancer Predisposition NGS panel
List of diseases covered by Cancer Predisposition NGS panel Gene Condition AIP Pituitary adenoma 1, multiple types ALK Neuroblastoma, susceptibility to, 3 APC Adenomatous polyposis coli; Colorectal cancer,
More informationNature Genetics: doi: /ng Supplementary Figure 1. Depths and coverages in whole-exome and targeted deep sequencing data.
Supplementary Figure 1 Depths and coverages in whole-exome and targeted deep sequencing data. Depth (top) and coverage (bottom) of whole-exome sequencing for 38 independent JPN cases (mean depth = 130)
More informationACTIVITY 2: EXAMINING CANCER PATIENT DATA
OVERVIEW Refer to the Overview of Cancer Discovery Activities for Key Concepts and Learning Objectives, Curriculum Connections, and Prior Knowledge, as well as background information, references, and additional
More informationWe are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university
Enhancing Assessment of Leukemia with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical i l Molecular l Laboratory City of Hope National Medical Center How the Expert Treat Hematologic
More informationSupplementary Figure 1. Copy Number Alterations TP53 Mutation Type. C-class TP53 WT. TP53 mut. Nature Genetics: doi: /ng.
Supplementary Figure a Copy Number Alterations in M-class b TP53 Mutation Type Recurrent Copy Number Alterations 8 6 4 2 TP53 WT TP53 mut TP53-mutated samples (%) 7 6 5 4 3 2 Missense Truncating M-class
More informationMSI positive MSI negative
Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden
More informationMultiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer Supplementary Materials Supplementary
More informationDetecting Oncogenic Mutations in Whole Blood
WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationParadigm Cancer Diagnostic (PCDx) 10 IHC results sample report
Date of Birth: PCDx Case#: Physician: Facility: Paradigm Cancer Diagnostic (PCDx) Case/Specimen ID: Collection Site: Collection Date: Received for testing: Turnaround: 4 business days Tumor cells: 100%
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature13898 Supplementary Information Table 1 Kras mutation status of carcinogen-induced mouse lung adenomas Tumour Treatment Strain Grade Genotype Kras status (WES)* Kras status (Sanger) 32T1
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationA brain tumor and NGS/multiplexing
A brain tumor and NGS/multiplexing Santiago Ramón y Cajal Jefe de Servicio. Hospital Vall d Hebron Catedrático de Anatomía Patológica U.A.B. Académico de Número de la Real Academia Nacional de Medicina
More informationDivision of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6
Page 1 of 6 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostic Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 Patient
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationSupplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each
Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each mutated gene and the panel of 125 cancer-driving genes
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationDisclosures. Objectives 1/20/2016. Practical Molecular Diagnostics in Lung Cancer: Beyond the NCCN Guidelines. Genentech: Scientific Advisory Board
Practical Molecular Diagnostics in Lung Cancer: Beyond the NCCN Guidelines Lynette M. Sholl, M.D. Department of Pathology Brigham and Women s Hospital Harvard Medical School Boston, MA Disclosures Genentech:
More informationThyroid Cancer Genomics. James A. Fagin MD Memorial Sloan Kettering Cancer Center
Thyroid Cancer Genomics James A. Fagin MD Memorial Sloan Kettering Cancer Center Disclosure Information James Fagin I have the following financial relationships to disclose: Consultant for: LOXO Oncology
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationTargeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders
Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University
More informationNext-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome
Clin Genet 2017: 91: 488 493 Printed in Singapore. All rights reserved Short Report 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12809 Next-generation
More informationOncomine Focus assay panel and Oncomine Knowledgebase Reporter.
Oncomine Focus assay panel and Oncomine Knowledgebase Reporter. How it can help to identify relevant alteration and early phase trials. Dr Isabelle SOUBEYRAN Dr Emmanuel KHALIFA Molecular Pathology Unit
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program
More informationWebinar Series. Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels. Participating experts
Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels April 13, 2016 Webinar Series Brought to you by the Science/ AAAS Custom Publishing Office Participating
More informationVersus. Cancer genomics Competitive Analysis
Cancer genomics Competitive Analysis Versus AGH Competitor #1 MYRIAD GENETICS, INC. Headquarters: UT, USA & Switzerland Publicly Traded Company - MYGN Founded: 1992 Company Size: 1001-5000 employees (source:
More informationThe Next Generation in Cancer Diagnostics.
The Next Generation in Cancer Diagnostics. OncoTarget was created specifically for cancer patients. Every patient s cancer is unique, which is why discovering what makes it unique can be essential for
More informationKarl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
Expanding on WHO guideline compliant molecular testing of central nervous system tumors by low density whole genome sequencing. Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Haematopathology and Oncology Diagnostic Services (HODS) Addenbrookes Hospital Hills Road Cambridge CB2 0QQ Contact: Brian Warner Tel: +44
More informationClinical, Pathologic and Molecular Updates
Colorectal Cancer: Clinical, Pathologic and Molecular Updates Joanna A. Gibson, M.D./Ph.D. Yale University School of Medicine/Yale New Haven Hospital, Department of Pathology Gastrointestinal, Pancreaticobiliary
More informationGenetic testing for hereditary cancer
Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of
More informationTGL clinical User Guide
TGL clinical User Guide The Institute of Cancer Research Brookes Lawley Building 15 Cotswold Road Sutton, Surrey SM2 5NG Page 1 of 7 TGL clinical This document describes the services provided by TGL clinical
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More information